233 related articles for article (PubMed ID: 23220414)
1. Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease.
Lewandowski NM; Bordelon Y; Brickman AM; Angulo S; Khan U; Muraskin J; Griffith EY; Wasserman P; Menalled L; Vonsattel JP; Marder K; Small SA; Moreno H
Neurobiol Dis; 2013 Apr; 52():84-93. PubMed ID: 23220414
[TBL] [Abstract][Full Text] [Related]
2. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
Kuhn A; Goldstein DR; Hodges A; Strand AD; Sengstag T; Kooperberg C; Becanovic K; Pouladi MA; Sathasivam K; Cha JH; Hannan AJ; Hayden MR; Leavitt BR; Dunnett SB; Ferrante RJ; Albin R; Shelbourne P; Delorenzi M; Augood SJ; Faull RL; Olson JM; Bates GP; Jones L; Luthi-Carter R
Hum Mol Genet; 2007 Aug; 16(15):1845-61. PubMed ID: 17519223
[TBL] [Abstract][Full Text] [Related]
3. Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.
Desplats PA; Lambert JR; Thomas EA
Neurobiol Dis; 2008 Sep; 31(3):298-308. PubMed ID: 18595722
[TBL] [Abstract][Full Text] [Related]
4. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
5. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
Xie Y; Hayden MR; Xu B
J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
[TBL] [Abstract][Full Text] [Related]
6. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse.
Brown TB; Bogush AI; Ehrlich ME
Hum Mol Genet; 2008 Oct; 17(20):3095-104. PubMed ID: 18632688
[TBL] [Abstract][Full Text] [Related]
7. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
8. Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.
Lee CY; Cantle JP; Yang XW
FEBS J; 2013 Sep; 280(18):4382-94. PubMed ID: 23829302
[TBL] [Abstract][Full Text] [Related]
9. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease.
Zuccato C; Belyaev N; Conforti P; Ooi L; Tartari M; Papadimou E; MacDonald M; Fossale E; Zeitlin S; Buckley N; Cattaneo E
J Neurosci; 2007 Jun; 27(26):6972-83. PubMed ID: 17596446
[TBL] [Abstract][Full Text] [Related]
10. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
11. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice.
Harris AS; Denovan-Wright EM; Hamilton LC; Robertson HA
J Psychiatry Neurosci; 2001 Mar; 26(2):117-22. PubMed ID: 11291528
[TBL] [Abstract][Full Text] [Related]
13. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
[TBL] [Abstract][Full Text] [Related]
14. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
Starling AJ; André VM; Cepeda C; de Lima M; Chandler SH; Levine MS
J Neurosci Res; 2005 Nov; 82(3):377-86. PubMed ID: 16211559
[TBL] [Abstract][Full Text] [Related]
15. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
16. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study.
Carty N; Berson N; Tillack K; Thiede C; Scholz D; Kottig K; Sedaghat Y; Gabrysiak C; Yohrling G; von der Kammer H; Ebneth A; Mack V; Munoz-Sanjuan I; Kwak S
PLoS One; 2015; 10(4):e0123527. PubMed ID: 25859666
[TBL] [Abstract][Full Text] [Related]
17. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
[TBL] [Abstract][Full Text] [Related]
18. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
Hebb AL; Robertson HA; Denovan-Wright EM
Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
[TBL] [Abstract][Full Text] [Related]
19. Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology.
Drouin-Ouellet J; Sawiak SJ; Cisbani G; Lagacé M; Kuan WL; Saint-Pierre M; Dury RJ; Alata W; St-Amour I; Mason SL; Calon F; Lacroix S; Gowland PA; Francis ST; Barker RA; Cicchetti F
Ann Neurol; 2015 Aug; 78(2):160-77. PubMed ID: 25866151
[TBL] [Abstract][Full Text] [Related]
20. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.
Menalled LB; Sison JD; Wu Y; Olivieri M; Li XJ; Li H; Zeitlin S; Chesselet MF
J Neurosci; 2002 Sep; 22(18):8266-76. PubMed ID: 12223581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]